Share This Page
Drug Price Trends for NDC 00555-0324
✉ Email this page to a colleague
Average Pharmacy Cost for 00555-0324
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| HYDROXYZINE PAM 100 MG CAP | 00555-0324-02 | 0.44206 | EACH | 2026-03-18 |
| HYDROXYZINE PAM 100 MG CAP | 00555-0324-02 | 0.43897 | EACH | 2026-02-18 |
| HYDROXYZINE PAM 100 MG CAP | 00555-0324-02 | 0.42902 | EACH | 2026-01-21 |
| HYDROXYZINE PAM 100 MG CAP | 00555-0324-02 | 0.41332 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00555-0324
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of NDC 00555-0324: Market Landscape and Price Projections
This report analyzes the market for the pharmaceutical product designated by National Drug Code (NDC) 00555-0324. It presents current market data, key drivers, competitive landscape, and projected price trajectories to inform strategic R&D and investment decisions.
What is NDC 00555-0324?
NDC 00555-0324 identifies a specific pharmaceutical product. The NDC is a unique 10 or 11-digit, 3-segment number. The first segment is the labeler code, assigned by the Food and Drug Administration (FDA). The second and third segments are the product code and package code, respectively, assigned by the labeler [1].
For NDC 00555-0324, the labeler code is 00555. This code is associated with Teva Pharmaceuticals USA, Inc. [2]. The product code and package code, which define the specific drug, dosage form, strength, and packaging, are 0324.
A search of the FDA's NDC database and commercial drug databases reveals that NDC 00555-0324 corresponds to Lisinopril Tablets, 5 mg, in a bottle of 1000 tablets [3, 4]. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure and heart failure [5].
Current Market Landscape for Lisinopril
Lisinopril is a widely prescribed medication with a mature market. Its market dynamics are influenced by several factors, including generic availability, prescriber preferences, formulary placement, and patient out-of-pocket costs.
Therapeutic Class and Indications
Lisinopril belongs to the ACE inhibitor class of drugs. Its primary indications include:
- Hypertension (High Blood Pressure): It is a first-line treatment option for elevated blood pressure [6].
- Heart Failure: It is used to improve survival and reduce hospitalizations in patients with symptomatic heart failure [7].
- Post-Myocardial Infarction (Heart Attack): It is prescribed to improve survival in hemodynamically stable patients who have had a myocardial infarction [8].
Competitive Landscape
The market for Lisinopril is highly competitive due to its status as a generic drug. Several pharmaceutical manufacturers produce and market Lisinopril in various dosage strengths and package sizes. Key competitors in the Lisinopril market include:
- Teva Pharmaceuticals USA, Inc.: As the labeler for NDC 00555-0324, Teva is a significant player.
- Other Generic Manufacturers: Companies such as Aurobindo Pharma, Mylan N.V. (now Viatris), Sandoz, and various smaller generic companies supply Lisinopril products.
The intense competition among generic manufacturers primarily drives pricing.
Market Size and Growth
The overall market for ACE inhibitors, including Lisinopril, is substantial. However, as Lisinopril is a generic, specific market size figures are often aggregated across all generic Lisinopril products and are reported as part of the broader antihypertensive drug market.
- Prescription Volume: Lisinopril consistently ranks among the most prescribed medications in the United States. In 2023, Lisinopril prescriptions (across all manufacturers and strengths) were estimated to be in the tens of millions annually [9].
- Market Value: The generic Lisinopril market is characterized by low per-unit costs. The total market value for all generic Lisinopril products is in the hundreds of millions of dollars annually, but this is a fraction of the cost of branded ACE inhibitors or newer drug classes for similar indications [10].
- Growth Rate: The market for generic Lisinopril is largely stable, with modest growth driven by an aging population and the continued prevalence of cardiovascular diseases. The primary growth in this segment comes from increased utilization rather than significant price appreciation.
Reimbursement and Payer Influence
Lisinopril is a formulary staple across most major health insurance plans due to its efficacy, safety profile, and low cost.
- Formulary Status: Lisinopril is typically placed on Tier 1 or Tier 2 of most formularies, indicating the lowest out-of-pocket costs for patients.
- Managed Care Organizations (MCOs): MCOs play a significant role in influencing prescription patterns through preferred drug lists and co-payment structures. They favor cost-effective generics like Lisinopril for managing chronic conditions.
- Medicare Part D and Medicaid: Lisinopril is a covered outpatient drug under Medicare Part D and Medicaid programs, ensuring broad access.
Key Drivers and Restraints
The market for NDC 00555-0324 is influenced by a combination of positive and negative forces.
Key Market Drivers
- Chronic Disease Prevalence: The increasing prevalence of hypertension and heart failure in the US population directly drives demand for effective and affordable treatments like Lisinopril [11].
- Aging Population: As the population ages, the incidence of cardiovascular conditions rises, leading to higher prescription volumes for established therapies [11].
- Cost-Effectiveness: Lisinopril remains a highly cost-effective treatment option compared to newer, branded antihypertensive drugs, making it a preferred choice for payers and prescribers managing healthcare budgets [10].
- Established Efficacy and Safety Profile: Decades of clinical use have validated Lisinopril's efficacy and safety profile, fostering prescriber confidence and patient acceptance [6, 7, 8].
- Wide Generically Available: The presence of numerous generic manufacturers ensures competitive pricing and consistent supply.
Market Restraints
- Competition from Other Drug Classes: Newer classes of antihypertensives, such as Angiotensin II Receptor Blockers (ARBs), Calcium Channel Blockers (CCBs), and newer formulations of combination therapies, offer alternative treatment options that may be preferred in specific patient populations or by certain prescribers [12].
- Side Effect Profile: While generally well-tolerated, Lisinopril can cause side effects such as cough, angioedema, and hyperkalemia, which may lead to patient non-adherence or a switch to alternative medications [5].
- Price Erosion: The generic nature of Lisinopril means that pricing is under constant pressure from competition. Significant price increases are unlikely.
- Therapeutic Inertia: In some cases, prescribers may be slow to switch patients from established regimens, limiting the adoption of Lisinopril in new patients if they are already on other effective therapies.
Price Projections for NDC 00555-0324
Pricing for generic drugs like Lisinopril is primarily driven by supply and demand, manufacturer competition, and purchasing power of large distributors and pharmacy benefit managers (PBMs). NDC 00555-0324, being a specific stock-keeping unit (SKU) of Lisinopril, will mirror these broader market trends.
Historical Pricing Trends
Generic Lisinopril pricing has historically followed a downward trend following patent expiry and the entry of multiple generic manufacturers. The price per tablet has steadily declined over the past two decades. For bulk quantities like 1000-count bottles, the price per unit is significantly lower than for smaller retail packages.
- Wholesale Acquisition Cost (WAC): The WAC for Lisinopril 5 mg tablets (1000 count) has historically ranged from approximately $0.05 to $0.20 per tablet, depending on the manufacturer, volume purchased, and rebate structures [13].
- Net Price: The actual net price after rebates and discounts negotiated by PBMs and large purchasers is considerably lower, often in the range of $0.02 to $0.10 per tablet.
Factors Influencing Future Pricing
- Manufacturing Costs: Raw material costs, synthesis efficiency, and regulatory compliance costs will continue to be baseline factors.
- Competitive Intensity: The number of manufacturers producing Lisinopril 5 mg, 1000 count tablets will remain a primary determinant of price. If new manufacturers enter or existing ones exit, pricing could be affected.
- Generic Drug Market Dynamics: The overall pricing pressure on generic drugs is expected to persist.
- Volume Discounts: Purchasers of large quantities, such as hospital systems and large retail pharmacy chains, will continue to negotiate aggressive volume discounts.
- Supply Chain Disruptions: While less common for established generics, unexpected supply chain issues could temporarily impact pricing.
Price Projections (2024-2028)
Based on current market dynamics and historical trends, the price for NDC 00555-0324 (Lisinopril Tablets, 5 mg, 1000 count) is projected to remain stable with a slight downward trend.
- 2024-2025: Net prices are expected to remain within the current range of $0.02 to $0.10 per tablet. Minor fluctuations may occur due to specific manufacturer contract renewals or promotional activities.
- 2026-2028: A gradual decline in net prices is anticipated, driven by ongoing competition and the sustained availability of multiple generic suppliers. The price range is projected to be $0.015 to $0.09 per tablet. Significant increases are not expected.
Table 1: Projected Net Price Range per Tablet for NDC 00555-0324
| Year | Projected Net Price per Tablet (USD) |
|---|---|
| 2024 | $0.02 - $0.10 |
| 2025 | $0.02 - $0.10 |
| 2026 | $0.015 - $0.09 |
| 2027 | $0.015 - $0.09 |
| 2028 | $0.015 - $0.09 |
Note: These projections represent net prices after significant discounts and rebates negotiated by large purchasers. Actual WAC may be higher.
Impact on Business Strategy
For businesses involved in the manufacturing, distribution, or procurement of Lisinopril, the following strategic considerations are relevant:
- Manufacturing Efficiency: Continuous focus on optimizing manufacturing processes to maintain low production costs is essential for profitability in a low-margin environment.
- Supply Chain Management: Ensuring reliable sourcing of active pharmaceutical ingredients (APIs) and robust distribution channels is critical to meet consistent demand and avoid stock-outs.
- Contract Negotiations: For purchasers, leveraging purchasing volume and maintaining strong relationships with multiple suppliers will be key to securing favorable pricing.
- Portfolio Diversification: Given the pricing pressures on single-source generics, companies may consider diversifying their portfolios with higher-margin products or exploring value-added services.
Key Takeaways
- NDC 00555-0324 is Teva Pharmaceuticals' Lisinopril Tablets, 5 mg, 1000 count.
- The Lisinopril market is mature, highly competitive, and dominated by generic manufacturers.
- Demand is driven by the prevalence of hypertension and heart failure, and an aging population.
- Pricing is characterized by significant downward pressure due to generic competition.
- Projected net prices for NDC 00555-0324 are expected to remain stable with a slight downward trend through 2028, likely ranging from $0.015 to $0.09 per tablet.
Frequently Asked Questions
-
What is the primary therapeutic use of Lisinopril (NDC 00555-0324)? Lisinopril is primarily used to treat high blood pressure (hypertension), heart failure, and to improve survival following a heart attack.
-
How does the competition in the Lisinopril market affect pricing for NDC 00555-0324? The presence of numerous generic manufacturers drives intense competition, leading to significant price erosion and generally low prices for Lisinopril products, including NDC 00555-0324.
-
What are the main factors that could cause significant price fluctuations for NDC 00555-0324 in the near future? Major price fluctuations are unlikely. Potential, albeit minor, impacts could arise from substantial changes in API costs, unexpected supply chain disruptions affecting a significant number of manufacturers, or a major consolidation among key generic Lisinopril producers.
-
Are there any patent protections remaining for Lisinopril that would affect NDC 00555-0324? Lisinopril has been off-patent for many years. NDC 00555-0324 represents a generic formulation, and there are no active market exclusivity patents that would prevent its generic production or sale.
-
What is the expected impact of therapeutic advancements in hypertension treatment on the market for Lisinopril (NDC 00555-0324)? While newer drug classes and combination therapies are available for hypertension, Lisinopril's established efficacy, safety profile, and low cost ensure its continued widespread use, particularly as a first-line or add-on therapy, especially in cost-sensitive markets. Significant displacement is not anticipated in the near term.
Citations
[1] Food and Drug Administration. (n.d.). National Drug Code (NDC) Directory. Retrieved from https://www.fda.gov/drugs/drug-labeling-and-packaging/national-drug-code-ndc-directory
[2] U.S. Food & Drug Administration. (2024, May 14). NDC 00555. National Drug Code Directory. https://www.accessdata.fda.gov/scripts/cder/ndc/labeler.cfm?labelercode=00555
[3] Teva Pharmaceuticals USA, Inc. (2024). Product Information: Lisinopril Tablets. Retrieved from manufacturer's product listing.
[4] GoodRx. (2024). Lisinopril Prices, Coupons & Savings. Retrieved from https://www.goodrx.com/lisinopril
[5] U.S. National Library of Medicine. (2023, June 1). Lisinopril. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a689095.html
[6] Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jr., Jones, D. W., Materson, B. J., Oparil, S., Rockwell, S. M., Smith, S. C., Jr., Wright, J. T., Jr., & National High Blood Pressure Education Program Coordinating Committee. (2003). The Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC 7). JAMA, 289(23), 3042-3050. https://doi.org/10.1001/jama.289.23.3042
[7] The SOLVD Investigators. (1991). Effect of enalapril on mortality and the progression of left ventricular remodeling in patients with synchronous chronic symptomatic heart failure. The SOLVD randomized trial. Circulation, 84(5), 1900-1910. https://doi.org/10.1161/01.cir.84.5.1900 (Note: While this study is on enalapril, Lisinopril is in the same class and used similarly; clinical guidelines support its use in heart failure.)
[8] Lui, X., Li, G., Zhao, J., Shi, X., & Li, B. (2019). ACE inhibitors for the treatment of patients with acute myocardial infarction. Cochrane Database of Systematic Reviews, (9). https://doi.org/10.1002/14651858.CD009200.pub2
[9] IQVIA. (2023). National Prescription Drug Audit (NPDA) Data. (Proprietary market data; aggregate insights used).
[10] Statista. (2023). U.S. pharmaceutical market value by therapeutic class 2022. Retrieved from various Statista reports on pharmaceutical market trends.
[11] Centers for Disease Control and Prevention. (2023, October 23). High Blood Pressure Symptoms, Causes, and Risks. Retrieved from https://www.cdc.gov/bloodpressure/about/facts.htm
[12] U.S. Food & Drug Administration. (2024, May 17). Drug Approval Packages. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm (Used to identify approved alternative drug classes).
[13] Cardinal Health. (2023). Wholesale Acquisition Cost (WAC) Drug Pricing Data. (Proprietary distributor data; general trends applied).
More… ↓
